Imbruvica: Withdrawal of the application to change the marketing authorisation

Janssen-Cilag International N.V. withdrew its application for the use of Imbruvica in combination with bendamustine and rituximab for patients with previously untreated mantle cell lymphoma (MCL, a cancer of a type of white blood cell called B cells).

The company withdrew the application on 13 December 2022.

More information are available  at EMA website page